Boehringer acquires licensing rights for Artilysin technology from Lysando

Boehringer Ingelheim Vetmedica has secured the licensing rights for the technology platform Artilysin®. The company is hopeful to receive significant momentum and solutions from this new substance class for the problem of multi-resistant bacteria, which also is an increasing threat to the animal world.

Artilysin®s are proteins that, through a physical mechanism, selectively eliminate pathogenic, multi-resistant and persisting bacteria. By way of license, Boehringer Ingelheim Vetmedica is taking advantage of the possibilities presented by this technology. The scope of applications for Artilysins spans from human and animal medicine to the food industry and the area of hygiene. They work quickly and with their "friend or foe" identification very specifically and are completely biodegradable. Additionally, no resistances occurred during the expansive studies. Multi-resistant bacteria pose a significant threat to health due to the increasing ineffectiveness of antibiotics. The EU Commission estimates the annual number of deaths caused by multi-resistant bacteria at 25,000. Massive economic effects are linked to this fact.

The Boehringer Ingelheim Group is among the 20 leading pharmaceutical companies worldwide. Their focus areas include research & development, production and marketing of new medicines with significant therapeutic benefits for human and animal health. In 2013, Boehringer Ingelheim reported revenues of appr. 14.1 bn Euros.

Lysando itself is not a manufacturer of pharmaceutical products nor will it become one in the future; it only provides its new technology platform through licensing. „The acquisition of licensing rights for the Artilysin® technology by Boehringer Ingelheim Vetmedica is a decisive step in the acceptance of this new class of substances", explains Markus Matuschka v. Greiffenclau, CEO of Lysando AG.